Trial of ARV-110 and Abiraterone in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Phase 1b study to assess the combination of ARV-110 and abiraterone in patients with metastatic prostate cancer with rising PSA values on abiraterone.
Prostate Cancer Metastatic
DRUG: ARV-110 in Combination with Abiraterone
Incidence of dose limiting toxicities of ARV-110 in combination with abiraterone, Dose limiting toxicities in first 4 weeks of the study combination treatment characterized by type, frequency, severity (as graded by NCI CTCAE v 5.0), timing, seriousness, and relationship to study drug, 4 weeks|Number of Patients with Adverse Events as a measure of safety and tolerability of ARV-110 in combination with abiraterone, Adverse events as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness, and relationship to study drug combination, 35 days after subject discontinues study treatment|Incidence of laboratory abnormalities as a measure of safety and tolerability of ARV-110 in combination with abiraterone, Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE v 5.0), and timing., 35 days after subject discontinues study treatment|Recommended Phase 2 dose (RP2D)/schedule for the combination, Dose limiting toxicities in first 4 weeks of the study combination treatment will be assessed to determine the dose of ARV-110 and abiraterone associated with acceptable safety and tolerability., 4 weeks
Phase 1b study to assess the combination of ARV-110 and abiraterone in patients with metastatic prostate cancer with rising PSA values on abiraterone.